740PFinal results of a phase II quality of life (QOL) randomized, cross-over (CO) study with gemcitabine (Gem) and nab-paclitaxel (n-P) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): QOLINPAC. (23rd October 2018) - Chiritescu, G; Dumon, K; Verslype, C; Houbiers, G; Peeters, M; Janssens, J; van Daele, D; Laurent, S; Arts, J; Hendrickx, K; Borbath, I; Ferrante, M; et al.